Evidence and Challenges for Translation and Population Impact of the Diabetes Prevention Program.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Current Science Country of Publication: United States NLM ID: 101093791 Publication Model: Electronic Cited Medium: Internet ISSN: 1539-0829 (Electronic) Linking ISSN: 15344827 NLM ISO Abbreviation: Curr Diab Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: Philadelphia, PA : Current Science, c2001-
    • Subject Terms:
      Diabetes Mellitus, Type 2/*prevention & control ; Prediabetic State/*prevention & control; Adult ; Exercise ; Health Promotion ; Humans ; Life Style ; Program Evaluation ; Public Health ; United States ; Weight Loss
    • Abstract:
      Purpose of Review: Type 2 diabetes is common, burdensome, and preventable. Landmark trials such as the Diabetes Prevention Program (DPP) demonstrated that resource-intensive lifestyle support interventions resulting in modest weight loss via healthy diet changes and physical activity can lower the rate of diabetes development by 58%. We performed a review of efforts to translate and implement DPP-like programs throughout the USA to identify challenges and opportunities for improvement.
      Recent Findings: For more than a decade, multiple stakeholders have worked to translate evidence-based principles of diabetes prevention to reach 84 million Americans with prediabetes. DPP-like programs have been delivered by over 1500 organizations, reaching almost 300,000 people, but this number represents less than 1% of the target population. Research has uncovered large gaps in efforts to diagnose, raise awareness, and provide access to DPP-like programs for adults with prediabetes, requiring further stakeholder engagement and coordination to resolve. Efforts to address prevailing gaps in diabetes prevention must address distinct and sometimes conflicting priorities and concerns of stakeholders. Our review recommends several areas of further research and action to improve type 2 diabetes prevention on a population scale.
    • References:
      Am J Prev Med. 2015 Oct;49(4):512-9. (PMID: 26091928)
      PLoS Med. 2016 Jul 12;13(7):e1002074. (PMID: 27403739)
      PLoS Med. 2016 Jul 26;13(7):e1002095. (PMID: 27459705)
      Transl Behav Med. 2020 Dec 31;10(6):1554-1558. (PMID: 31228199)
      J Med Internet Res. 2011 Mar 10;13(1):e30. (PMID: 21393123)
      Diabetes Care. 2003 Jan;26(1):36-47. (PMID: 12502656)
      Curr Diab Rep. 2019 Aug 5;19(9):78. (PMID: 31385061)
      JAMA Netw Open. 2019 May 3;2(5):e193160. (PMID: 31074808)
      Diabetes Educ. 2007 Jan-Feb;33(1):69, 74-5, 77-8. (PMID: 17272794)
      Diabetes Care. 2005 Apr;28(4):888-94. (PMID: 15793191)
      J Acquir Immune Defic Syndr. 2014 Aug 15;66 Suppl 3:S329-40. (PMID: 25007204)
      Lancet Diabetes Endocrinol. 2017 Jan;5(1):34-42. (PMID: 27863979)
      Am J Public Health. 2015 Nov;105(11):2328-34. (PMID: 26378828)
      Prev Med Rep. 2018 Jun 18;11:131-138. (PMID: 30003011)
      J Gen Intern Med. 2019 Nov;34(11):2475-2481. (PMID: 31502095)
      Diabetes Care. 2011 Feb;34(2):387-91. (PMID: 21270196)
      J Gen Intern Med. 2012 Dec;27(12):1594-601. (PMID: 22692637)
      J Am Coll Cardiol. 2010 Mar 30;55(13):1310-7. (PMID: 20338491)
      Ann Intern Med. 2015 Dec 1;163(11):861-8. (PMID: 26501513)
      BMC Public Health. 2011 Feb 27;11:136. (PMID: 21352562)
      Am J Health Promot. 2019 Mar;33(3):372-380. (PMID: 30021451)
      J Am Board Fam Med. 2019 Jul-Aug;32(4):505-512. (PMID: 31300570)
      Diabetologia. 2006 Feb;49(2):289-97. (PMID: 16391903)
      Nutr Diabetes. 2018 May 25;8(1):33. (PMID: 29795365)
      Ann Intern Med. 2015 Sep 15;163(6):452-60. (PMID: 26167962)
      Health Aff (Millwood). 2012 Jan;31(1):50-60. (PMID: 22232094)
      Ann Intern Med. 2014 Oct 21;161(8):587-93. (PMID: 25155419)
      Ann Intern Med. 2011 Oct 4;155(7):434-47. (PMID: 21969342)
      Health Aff (Millwood). 2012 Jan;31(1):67-75. (PMID: 22232096)
      Diabetes Care. 2017 Oct;40(10):1331-1341. (PMID: 28500215)
      Am J Prev Med. 2013 Apr;44(4 Suppl 4):S301-6. (PMID: 23498291)
      N Engl J Med. 2001 May 3;344(18):1343-50. (PMID: 11333990)
      Prev Chronic Dis. 2018 Sep 06;15:E109. (PMID: 30191810)
      Diabetes Care. 1997 Apr;20(4):537-44. (PMID: 9096977)
      Diabetes Spectr. 2018 Nov;31(4):310-319. (PMID: 30510385)
      Ann Intern Med. 2005 Mar 1;142(5):323-32. (PMID: 15738451)
      Ann Behav Med. 2012 Dec;44(3):375-88. (PMID: 22907712)
      Curr Diab Rep. 2012 Apr;12(2):138-46. (PMID: 22350807)
      Diabetes Care. 2014 Apr;37(4):922-33. (PMID: 24652723)
      Lancet. 2012 Jun 16;379(9833):2279-90. (PMID: 22683128)
      Med Care. 2002 Jan;40(1):38-51. (PMID: 11748425)
      Diabetes Care. 2003 Nov;26(11):3160-7. (PMID: 14578255)
      N Engl J Med. 2002 Feb 7;346(6):393-403. (PMID: 11832527)
      Am J Public Health. 2003 Apr;93(4):635-41. (PMID: 12660210)
      Clin Diabetes. 2018 Jan;36(1):59-66. (PMID: 29382980)
      Am J Prev Med. 2018 Aug;55(2):e39-e47. (PMID: 29934016)
      J Gen Intern Med. 2015 Feb;30(2):214-20. (PMID: 25373836)
      Diabetes Care. 2019 Sep;42(9):1776-1783. (PMID: 31010870)
      Am J Public Health. 2008 May;98(5):916-24. (PMID: 18381998)
      J Gen Intern Med. 2019 Nov;34(11):2652-2659. (PMID: 31471729)
      Am J Prev Med. 2013 Apr;44(4 Suppl 4):S346-51. (PMID: 23498297)
      Clin Trials. 2017 Feb;14(1):29-36. (PMID: 27646508)
    • Grant Information:
      R18 HS026172 United States HS AHRQ HHS
    • Contributed Indexing:
      Keywords: Diabetes prevention; Dissemination of evidence; Implementation challenges; Prediabetes; Type 2 diabetes
    • Publication Date:
      Date Created: 20200222 Date Completed: 20200911 Latest Revision: 20240518
    • Publication Date:
      20240518
    • Accession Number:
      PMC11100316
    • Accession Number:
      10.1007/s11892-020-1293-4
    • Accession Number:
      32080770